Study of HLX37 for advanced solid tumors that haven't responded to treatment
Part of Cancer clinical trials.
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced or metastatic solid tumor that has continued to grow despite at least one standard treatment, or no effective standard treatment exists.
- You need to be between 18 and 75 years old and in generally good health (able to do daily activities without much help).
- You must have at least one measurable tumor (visible on scans) that hasn't been treated with radiation or has grown after radiation.
- You cannot have active or untreated brain metastases, interstitial lung disease, or certain heart or bleeding conditions.
- You must be willing to provide a tumor tissue sample (from a recent biopsy or surgery) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
This trial tests a new daily pill called HLX97 for people with advanced cancers that have stopped responding to standard treatments. It may help if you have a type of breast cancer that is hormone-receptor positive and HER2-negative, or castration-resistant prostate cancer, or non-small cell lung cancer.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.